Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 3/20 | 0.79 |
| ▸ | CDK1 | P06493 | 2/20 | 0.79 |
| ▸ | CDK2 | P24941 | 2/20 | 0.79 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.79 |
| ▸ | GSK3B | P49841 | 1/20 | 0.79 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.79 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.79 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.79 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.79 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.79 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.79 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.79 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.79 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.79 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.79 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.79 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 6/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.40 |
| ▸ | CSF1R | P07333 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4059247 | 0.99 | CDK7 (0.78) | CDK7CDK1CDK2DYRK3GSK3B | |
| SCHEMBL4059706 | 0.96 | CDK7 (0.74) | CDK7CDK1CDK2DYRK3GSK3B | |
| Hydrochloric Acid SCHEMBL4066949 | 0.95 | CDK7 (0.73) | CDK7CDK1CDK2DYRK3GSK3B | |
| Hydrochloric Acid SCHEMBL3198965 | 0.91 | CDK7 (0.66) | CDK7CDK1CDK2DYRK3GSK3B | |
| SCHEMBL4016405 | 0.91 | CDK7 (0.83) | CDK7CDK1CDK2DYRK3GSK3B | |
| SCHEMBL4062352 | 0.91 | CDK7 (0.83) | CDK7CDK1CDK2DYRK3GSK3B | |
| SCHEMBL4019774 | 0.90 | CDK7 (0.82) | CDK7CDK1CDK2DYRK3GSK3B | |
| Hydrochloric Acid SCHEMBL4066905 | 0.90 | CDK7 (0.82) | CDK7CDK1CDK2DYRK3GSK3B | |
| SCHEMBL4059903 | 0.89 | CDK7 (0.76) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL29361806 | 0.88 | CDK7 (1.00) | CDK7CDK1CDK2DYRK3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492785-B9 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | claimed |
| CN-100519550-C | 2-oxoindole compounds having inhibitory activity on glycogen synthase kinase 3 receptor | ASTRAZENECA AB SE (SE) | 2009-07-29 | — | — | CN | claimed |
| US-20090149460-A1 | New Compounds | BERG STEFAN | 2009-06-11 | — | — | US | claimed |
| WO-2009017454-A1 | NEW THERAPEUTIC COMBINATION OF A GSK3 INHIBITOR AND AN A7-NICOTINIC AGONIST 960 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| WO-2009017453-A1 | NEW THERAPEUTIC COMBINATION OF AN ANTIPSYCHOTIC AND A GSK3 INHIBITOR 958 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| WO-2009017455-A1 | A NEW COMBINATION OF (A) AN ALPHA-4-BETA-2 -NEURONAL NICOTINIC AGONIST AND (B) A GSK3 INHIBITOR | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| EP-1492785-B1 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | claimed |
| US-7399780-B2 | 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2008-07-15 | — | — | US | claimed |
| CN-1642938-A | Novel compounds | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | claimed |
| US-20230115252-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | UNIVERSITÉ PARIS CITÉ (FR) | 2023-04-13 | — | — | US | disclosed |
| EP-3741375-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-11-25 | — | — | EP | disclosed |
| US-20200323900-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2020-10-15 | — | — | US | disclosed |
| US-20170209488-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-07-27 | — | — | US | disclosed |
| EP-3169337-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-05-24 | — | — | EP | disclosed |
| CN-100519550-C | 2-oxoindole compounds having inhibitory activity on glycogen synthase kinase 3 receptor | ASTRAZENECA AB SE (SE) | 2009-07-29 | — | — | CN | disclosed |
| WO-2009017454-A1 | NEW THERAPEUTIC COMBINATION OF A GSK3 INHIBITOR AND AN A7-NICOTINIC AGONIST 960 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017453-A1 | NEW THERAPEUTIC COMBINATION OF AN ANTIPSYCHOTIC AND A GSK3 INHIBITOR 958 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017455-A1 | A NEW COMBINATION OF (A) AN ALPHA-4-BETA-2 -NEURONAL NICOTINIC AGONIST AND (B) A GSK3 INHIBITOR | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| CN-1923812-A | New compounds | ASTRAZENECA AB (SE) | 2007-03-07 | — | — | CN | disclosed |
| CN-1642938-A | Novel compounds | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149460-A1 | New Compounds | SDHA, CYP11B2, SERPINB1 | CDK7 444/4885CDK1 263/4885CDK2 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.